<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558400</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS301</org_study_id>
    <nct_id>NCT02558400</nct_id>
  </id_info>
  <brief_title>Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to
      Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.

      Following completion of the Month 12 study visit procedures, subjects will be offered the
      opportunity to participate in a 2-month observational (i.e., non-interventional) trial
      extension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)</time_frame>
    <description>The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of Exposure</measure>
    <time_frame>12 months</time_frame>
    <description>Exposure to study medication in days for all treatment groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">718</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>PG324 Ophthalmic Solution 0.02%/0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13324 Ophthalmic Solution 0.02%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Netarsudil 0.02% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost Ophthalmic Solution 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG324 Ophthalmic Solution 0.02%/0.005%</intervention_name>
    <description>1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
    <arm_group_label>PG324 Ophthalmic Solution 0.02%/0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil (AR-13324) Ophthalmic Solution 0.02%</intervention_name>
    <description>1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
    <arm_group_label>AR-13324 Ophthalmic Solution 0.02%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost Ophthalmic Solution 0.005%</intervention_name>
    <description>1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
    <arm_group_label>Latanoprost Ophthalmic Solution 0.005%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes

          3. Unmedicated intraocular pressure &gt;20mmHg and &lt;36mmHg in both eyes at 2 qualification
             visits. Both eyes had to qualify at all qualification visits

          4. Corrected visual acuity equivalent to 20/200 Snellen or better

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             or narrow angles

          3. Unmedicated Intraocular pressure ≥36mmHg

          4. Use of more than 2 ocular hypotensive medications within 30 days of screening

          5. Known hypersensitivity to any component of the formulation

          6. Previous glaucoma surgery or refractive surgery

          7. Ocular trauma within 6 months prior to screening

          8. Any ocular surgery or non-refractive laser treatment within 3 months prior to
             screening

          9. Recent or current ocular infection or inflammation in either eye

         10. Used ocular medication in either eye of any kind within 30 days of screening

         11. Mean central corneal thickness &gt;620µm at screening

         12. Any abnormality preventing reliable applanation tonometry of either eye

         13. Clinically significant abnormalities in lab tests at screening

         14. Clinically significant systemic disease

         15. Participation in any investigational study within 60 days prior to screening

         16. Used any systemic medication that could have a substantial effect on intraocular
             pressure within 30 days prior to screening

         17. Women who are pregnant, nursing, planning a pregnancy or not using a medically
             acceptable form of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Heah, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aerie Pharmaceuticals</name>
      <address>
        <city>Bedminster</city>
        <state>New Jersey</state>
        <zip>07921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <results_first_submitted>April 11, 2019</results_first_submitted>
  <results_first_submitted_qc>May 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <disposition_first_submitted>April 12, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 17, 2018</disposition_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02558400/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02558400/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PG324 Ophthalmic Solution 0.02%/0.005%</title>
          <description>PG324 Ophthalmic Solution: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="P2">
          <title>AR-13324 Ophthalmic Solution 0.02%</title>
          <description>Netarsudil (AR-13324) Ophthalmic Solution 0.02%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="P3">
          <title>Latanoprost Ophthalmic Solution 0.005%</title>
          <description>Latanoprost Ophthalmic Solution 0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="244"/>
                <participants group_id="P3" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disallowed Concurrent Medication</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible for the study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PG324 Ophthalmic Solution</title>
          <description>PG324 Ophthalmic Solution: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="B2">
          <title>AR-13324 Ophthalmic Solution 0.02%</title>
          <description>Netarsudil (AR-13324) Ophthalmic Solution 0.02%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="B3">
          <title>Latanoprost Ophthalmic Solution 0.005%</title>
          <description>Latanoprost Ophthalmic Solution 0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="238"/>
            <count group_id="B2" value="244"/>
            <count group_id="B3" value="236"/>
            <count group_id="B4" value="718"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="11.33"/>
                    <measurement group_id="B2" value="64.6" spread="10.97"/>
                    <measurement group_id="B3" value="65.4" spread="10.98"/>
                    <measurement group_id="B4" value="64.8" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="626"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="486"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment.</description>
        <time_frame>Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>PG324 Ophthalmic Solution</title>
            <description>PG324 Ophthalmic Solution: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
          <group group_id="O2">
            <title>AR-13324 Ophthalmic Solution 0.02%</title>
            <description>Netarsudil (AR-13324) Ophthalmic Solution 0.02%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
          <group group_id="O3">
            <title>Latanoprost Ophthalmic Solution 0.005%</title>
            <description>Latanoprost Ophthalmic Solution 0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment.</description>
          <population>Intent to Treat (ITT) population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0800 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.84" spread="3.316"/>
                    <measurement group_id="O2" value="24.81" spread="3.335"/>
                    <measurement group_id="O3" value="24.59" spread="2.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1000 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.72" spread="3.587"/>
                    <measurement group_id="O2" value="23.45" spread="3.510"/>
                    <measurement group_id="O3" value="23.43" spread="3.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1600 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.59" spread="3.610"/>
                    <measurement group_id="O2" value="22.63" spread="3.674"/>
                    <measurement group_id="O3" value="23.43" spread="3.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 0800 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.68" spread="3.532"/>
                    <measurement group_id="O2" value="18.66" spread="4.189"/>
                    <measurement group_id="O3" value="17.74" spread="3.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1000 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.93" spread="3.417"/>
                    <measurement group_id="O2" value="17.78" spread="4.219"/>
                    <measurement group_id="O3" value="17.36" spread="3.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1600 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="2.978"/>
                    <measurement group_id="O2" value="17.25" spread="3.814"/>
                    <measurement group_id="O3" value="17.11" spread="3.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 0800 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.04" spread="3.268"/>
                    <measurement group_id="O2" value="19.06" spread="4.593"/>
                    <measurement group_id="O3" value="17.58" spread="3.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 1000 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="3.175"/>
                    <measurement group_id="O2" value="17.92" spread="4.168"/>
                    <measurement group_id="O3" value="17.06" spread="3.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 1600 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" spread="3.065"/>
                    <measurement group_id="O2" value="17.54" spread="3.855"/>
                    <measurement group_id="O3" value="16.97" spread="3.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90, 0800 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.37" spread="3.377"/>
                    <measurement group_id="O2" value="19.04" spread="4.537"/>
                    <measurement group_id="O3" value="17.53" spread="3.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90, 1000 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.41" spread="3.038"/>
                    <measurement group_id="O2" value="17.96" spread="4.262"/>
                    <measurement group_id="O3" value="16.88" spread="3.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90, 1600 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.49" spread="3.126"/>
                    <measurement group_id="O2" value="17.30" spread="3.769"/>
                    <measurement group_id="O3" value="16.67" spread="3.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To claim superiority PG324 had to be statistically superior to netarsudil and to latanoprost at all 9 of 9 primary efficacy timepoints</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>PG324 vs. netarsudil</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>PG324 vs. latanoprost</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Exposure</title>
        <description>Exposure to study medication in days for all treatment groups</description>
        <time_frame>12 months</time_frame>
        <population>The safety population= all randomized subjects who received at least 1 dose of study medication. The safety population summarized subjects as-treated. 1 Subject was randomized to netarsudil but received latanoprost. Therefore, 1 less subject is in the netarsudil group and 1 additional subject is in the latanoprost group for the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>PG324 Ophthalmic Solution 0.02%/0.005%</title>
            <description>Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
PG324 Ophthalmic Solution 0.02%/0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
          <group group_id="O2">
            <title>AR-13324 Ophthalmic Solution 0.02%</title>
            <description>Netarsudil 0.02% ophthalmic solution
Netarsudil (AR-13324) Ophthalmic Solution 0.02%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
          <group group_id="O3">
            <title>Latanoprost Ophthalmic Solution 0.005%</title>
            <description>Latanoprost 0.005% ophthalmic solution
Latanoprost Ophthalmic Solution 0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Exposure</title>
          <description>Exposure to study medication in days for all treatment groups</description>
          <population>The safety population= all randomized subjects who received at least 1 dose of study medication. The safety population summarized subjects as-treated. 1 Subject was randomized to netarsudil but received latanoprost. Therefore, 1 less subject is in the netarsudil group and 1 additional subject is in the latanoprost group for the safety population.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.7" spread="129.94"/>
                    <measurement group_id="O2" value="266.2" spread="131.60"/>
                    <measurement group_id="O3" value="330.4" spread="89.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the course of the study of 12 month treatment and 2 month safety follow up.The safety population summarized subjects as-treated.</time_frame>
      <desc>Safety population, defined as all randomized subjects who received at least 1 dose of investigational product.The safety population summarized subjects as-treated. 1 Subject was randomized to netarsudil but received latanoprost. Therefore, 1 less subject is in the netarsudil group and 1 additional subject is in the latanoprost group for the safety population. (applies to the numbers of subjects for SAEs, all cause mortality and other AEs sections)</desc>
      <group_list>
        <group group_id="E1">
          <title>PG324 Ophthalmic Solution</title>
          <description>PG324 Ophthalmic Solution: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="E2">
          <title>AR-13324 Ophthalmic Solution 0.02%</title>
          <description>Netarsudil (AR-13324) Ophthalmic Solution 0.02%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="E3">
          <title>Latanoprost Ophthalmic Solution 0.005%</title>
          <description>Latanoprost Ophthalmic Solution 0.005%: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Impaired Gastric Emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastric Cancer Recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intraductal Proliferative Breast Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" events="133" subjects_affected="133" subjects_at_risk="238"/>
                <counts group_id="E2" events="115" subjects_affected="115" subjects_at_risk="243"/>
                <counts group_id="E3" events="44" subjects_affected="44" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cornea Verticillata</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="238"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="243"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="238"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="243"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Pain</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="238"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="243"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa GH Heah, MD, MBA</name_or_title>
      <organization>Aerie Pharmaceuticals, Inc</organization>
      <phone>908-947-3844</phone>
      <email>theah@aeriepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

